Row Erupts Over “Third Way” For Biosimilar Approvals In Colombia
Executive Summary
Colombia’s health ministry has accused the R&D-based pharmaceutical industry association of prioritizing monopolies over patients after its attempts to suspend legislation that promises a faster route to market for biosimilars.